GLP-1 agonists like semaglutide and tirzepatide are transforming the management of obesity and type 2 diabetes. This article examines their mechanisms, benefits, risks, and the profound implications for public health.
ScienceToday.ai delivers accurate, engaging, and search-optimized science stories designed for curious readers, educators, and professionals.
GLP-1 agonists like semaglutide and tirzepatide are transforming the management of obesity and type 2 diabetes. This article examines their mechanisms, benefits, risks, and the profound implications for public health.
## Introduction Type 2 diabetes has emerged as one of the most pressing public health challenges of the 21st century, affecting hundreds of millions of people worldwide. Once considered a disease of adulthood, it is now…
## Introduction Artificial Intelligence (AI) has rapidly evolved from a futuristic concept to a transformative force in many sectors, but nowhere is its impact more profound and immediate than in healthcare. The integra…